| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.24 | 5e-06 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | -0.15 | 9e-06 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.14 | 3e-05 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.23 | 3e-05 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | -0.15 | 7e-05 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0001 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0002 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | -0.1 | 0.0004 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.18 | 0.0005 |